<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930293</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH085874</org_study_id>
    <secondary_id>R01MH085874</secondary_id>
    <secondary_id>MH085874-01</secondary_id>
    <secondary_id>PRO08070009</secondary_id>
    <secondary_id>PCC: DSIR 84-CT</secondary_id>
    <nct_id>NCT00930293</nct_id>
  </id_info>
  <brief_title>Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety</brief_title>
  <official_title>Personalizing Treatment of Depression Complicated by Panic Features-Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the feasibility and efficacy of a personalized psychotherapy&#xD;
      treatment for people with depression and co-occurring anxiety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately one half of all depressed psychiatric patients also meet the criteria for an&#xD;
      anxiety disorder. Compared to people with only depression, people with both depression and&#xD;
      panic features experience poorer psychological and social functioning, a greater risk of&#xD;
      suicide, less response to medication and therapy treatment, and a greater risk of recurring&#xD;
      symptoms. Because people with depression and co-occurring anxiety features do not achieve&#xD;
      full symptom remission with either medication or therapy alone, this study will use a&#xD;
      treatment that combines the two. A commonly used type of depression medication called a&#xD;
      selective serotonin reuptake inhibitor (SSRI) will be combined with a specialized therapy&#xD;
      developed to address depression with co-occurring symptoms of panic, anxiety, and avoidance.&#xD;
      This study will also test a computer-based method of assessing mood and anxiety symptom&#xD;
      profiles and outcomes to determine whether participants find this method acceptable and&#xD;
      clinicians find it useful.&#xD;
&#xD;
      Participation in this study will last 20 weeks, with follow-up visits occurring 4 and 8&#xD;
      months after starting. Participants will be randomly assigned to receive either an&#xD;
      individualized therapy for depression and anxiety, called interpersonal psychotherapy for&#xD;
      depression with panic and anxiety symptoms (IPT-PS), or a standard therapy for depression,&#xD;
      called brief supportive psychotherapy (BSP). All participants will complete up to 16 therapy&#xD;
      sessions and receive a standard SSRI treatment with the medication citalopram hydrobromide.&#xD;
      During the IPT-PS treatment, a study therapist will examine regular computer updates of&#xD;
      depression and anxiety scores for participants and talk to them about identifying and&#xD;
      addressing life stressors that trigger symptoms. During the BSP treatment, a study therapist&#xD;
      will encourage participants to arrive at their own solutions by emphasizing the participants'&#xD;
      strengths and examining what has worked in the past.&#xD;
&#xD;
      Participants will complete assessments weekly during the 20 weeks of the study intervention&#xD;
      and at 4- and 8-month follow-up visits. These assessments will include self-report&#xD;
      questionnaires about symptoms, medication side effects, and treatment adherence; vital sign&#xD;
      and weight measurements; and a clinical interview. Regular assessments of medication&#xD;
      effectiveness and side effects will occur every 1 to 4 weeks. Starting at the second study&#xD;
      visit, participants will also complete monthly computer-based questionnaires about depression&#xD;
      and anxiety symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Meeting Depression Remission Criteria</measure>
    <time_frame>Measured at baseline and weekly for up to 20 weeks of acute treatment</time_frame>
    <description>Depression remission defined as 3 consecutive weeks of HRSD-17 scores that on average, &lt; or = 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weeks to Depression Remission</measure>
    <time_frame>Measured at baseline and weekly for up to 20 weeks of treatment</time_frame>
    <description>Kaplan-Meier survival analyses to determine time to depression remission (defined as average HRSD-17 score &lt; or = 7 for three consecutive weeks).&#xD;
Analyses run with the full intent to treat sample (censoring patients who dropped out at time of termination)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Personalized Depression Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication (citalopram) treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Depression Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication (citalopram) treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)</intervention_name>
    <description>16 weekly IPT-PS sessions, each lasting approximately 45 minutes</description>
    <arm_group_label>Personalized Depression Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Supportive Psychotherapy (BSP)</intervention_name>
    <description>16 weekly BPS sessions, each lasting approximately 45 minutes</description>
    <arm_group_label>Standard Depression Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram hydrobromide</intervention_name>
    <description>A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
    <arm_group_label>Personalized Depression Care</arm_group_label>
    <arm_group_label>Standard Depression Care</arm_group_label>
    <other_name>Celexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently in an episode of nonpsychotic major depression, as defined by the DSM-IV and&#xD;
             documented by both the Structured Clinical Interview for Axis I, DSM-IV Disorders&#xD;
             (SCID) and by a rating of greater than 15 on the 25-item Hamilton Rating Scale for&#xD;
             Depression (HRSD)&#xD;
&#xD;
          -  Panic spectrum risk category of at least 7, as defined by the Panic-Agoraphobic&#xD;
             Spectrum Self-Report (PAS-SR), last month version&#xD;
&#xD;
          -  Not currently receiving effective treatment&#xD;
&#xD;
          -  Participants with suicidal ideation are eligible as long as outpatient treatment is&#xD;
             deemed safe.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of manic or hypomanic episode(s)&#xD;
&#xD;
          -  History of schizophrenia or schizoaffective disorder&#xD;
&#xD;
          -  Mood disorder due to a general medical condition or induced by substance use&#xD;
&#xD;
          -  Presence of psychosis&#xD;
&#xD;
          -  Current pregnancy or plans to become pregnant&#xD;
&#xD;
          -  Current primary diagnosis of anorexia nervosa or bulimia nervosa (this does not&#xD;
             include an eating disorder not otherwise specified [NOS])&#xD;
&#xD;
          -  Current primary diagnosis of severe obsessive-compulsive disorder (OCD), as determined&#xD;
             by clinician evaluation of symptom severity and temporal onset of symptoms&#xD;
&#xD;
          -  Drug or alcohol abuse or dependence within the past 3 months (participants with&#xD;
             episodic abuse related to mood episodes will not be excluded)&#xD;
&#xD;
          -  Satisfies full DSM-IV criteria for antisocial personality disorder, as determined by&#xD;
             SCID-II evaluation&#xD;
&#xD;
          -  Requires inpatient treatment because of suicidal risk or psychotic symptoms (current&#xD;
             suicidal thinking or parasuicidal behavior is not exclusionary if, in clinician&#xD;
             judgment, it can be managed on an outpatient basis)&#xD;
&#xD;
          -  Any of the following medical conditions:&#xD;
&#xD;
               1. An index episode that is secondary to the effect of medically prescribed drugs,&#xD;
                  i.e., reserpine, antihistamines, etc.&#xD;
&#xD;
               2. Presence of significant uncontrolled medical illness including cardiovascular&#xD;
                  disorder, kidney or liver disease, epilepsy, untreated hypertension, or&#xD;
                  unstabilized endocrine disease (stable medical conditions such as well-controlled&#xD;
                  diabetes or HIV positive status are not exclusionary provided the participant&#xD;
                  meets other inclusion and exclusion criteria)&#xD;
&#xD;
               3. Current treatment with a pharmacologic, over-the-counter, or herbal therapy for&#xD;
                  depression or anxiety (unless the participant wishes to discontinue an&#xD;
                  ineffective treatment)&#xD;
&#xD;
          -  History of poor or failed treatment response to an adequate dose and duration of&#xD;
             citalopram&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill M. Cyranowski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>June 26, 2009</study_first_submitted>
  <study_first_submitted_qc>June 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <results_first_submitted>December 19, 2013</results_first_submitted>
  <results_first_submitted_qc>January 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2016</results_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jill Cyranowski</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry and Psychology</investigator_title>
  </responsible_party>
  <keyword>Interpersonal Psychotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Personalized Depression Care</title>
          <description>Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.&#xD;
Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Standard Depression Care</title>
          <description>Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.&#xD;
Brief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Personalized Depression Care</title>
          <description>Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.&#xD;
Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Standard Depression Care</title>
          <description>Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.&#xD;
Brief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.37" spread="11.41"/>
                    <measurement group_id="B2" value="31.09" spread="10.27"/>
                    <measurement group_id="B3" value="30.74" spread="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Meeting Depression Remission Criteria</title>
        <description>Depression remission defined as 3 consecutive weeks of HRSD-17 scores that on average, &lt; or = 7</description>
        <time_frame>Measured at baseline and weekly for up to 20 weeks of acute treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Personalized Depression Care</title>
            <description>Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.&#xD;
Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Standard Depression Care</title>
            <description>Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.&#xD;
Brief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting Depression Remission Criteria</title>
          <description>Depression remission defined as 3 consecutive weeks of HRSD-17 scores that on average, &lt; or = 7</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weeks to Depression Remission</title>
        <description>Kaplan-Meier survival analyses to determine time to depression remission (defined as average HRSD-17 score &lt; or = 7 for three consecutive weeks).&#xD;
Analyses run with the full intent to treat sample (censoring patients who dropped out at time of termination)</description>
        <time_frame>Measured at baseline and weekly for up to 20 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Personalized Depression Care</title>
            <description>Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.&#xD;
Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Standard Depression Care</title>
            <description>Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.&#xD;
Brief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Weeks to Depression Remission</title>
          <description>Kaplan-Meier survival analyses to determine time to depression remission (defined as average HRSD-17 score &lt; or = 7 for three consecutive weeks).&#xD;
Analyses run with the full intent to treat sample (censoring patients who dropped out at time of termination)</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.99" spread="1.47"/>
                    <measurement group_id="O2" value="11.59" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Personalized Depression Care</title>
          <description>Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication treatment.&#xD;
Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS): 16 weekly IPT-PS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Standard Depression Care</title>
          <description>Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication treatment.&#xD;
Brief Supportive Psychotherapy (BSP): 16 weekly BPS sessions, each lasting approximately 45 minutes&#xD;
Citalopram hydrobromide: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unexplained Visual Disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jill M. Cyranowski, PhD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-246-5588</phone>
      <email>cyranowskijm@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

